676500-39-3

Basic information

• Product Name: 2,3-Difluoro-4-hydroxybenzaldehyde
• Synonyms: Benzaldehyde, 2,3-difluoro-4-hydroxy- (9CI);2,3-Difluoro-4-hydroxybenzaldehyde97%
• CAS NO: 676500-39-3
• Molecular Formula: C₇H₄F₂O₂
• Molecular Weight: 158.1022664
• Product Categories: ALDEHYDE;HALIDE;ALCOHOL
• Mol File: 676500-39-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 140-144℃
• Boiling Point: 235.4 °C at 760 mmHg
• Flash Point: 96.2 °C
• Appearance: /
• Density: 1.464 g/cm³
• Vapor Pressure: 0.0328mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.54±0.23(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2,3-Difluoro-4-hydroxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Difluoro-4-hydroxybenzaldehyde(676500-39-3)
• EPA Substance Registry System: 2,3-Difluoro-4-hydroxybenzaldehyde(676500-39-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 676500-39-3(Hazardous Substances Data)

Usage

General Description

2,3-Difluoro-4-hydroxybenzaldehyde is a chemical compound with the molecular formula C7H4F2O2. It is a derivative of benzaldehyde, with two fluorine atoms and a hydroxyl group attached to the benzene ring. 2,3-Difluoro-4-hydroxybenzaldehyde is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has properties that make it useful in the production of a wide range of products, including dyes, fragrances, and flavoring agents. Additionally, 2,3-Difluoro-4-hydroxybenzaldehyde has potential applications in the development of new materials and as a research tool in organic chemistry.

InChI:InChI=1/C7H4F2O2/c8-6-4(3-10)1-2-5(11)7(6)9/h1-3,11H

Upstream product

• 1010800-88-0 2,3-difluoro-4-((triisopropylsilyl)oxy)benzoic acid 
• 6418-38-8 2,3-difluorophenol 
• 749230-30-6 (2,3-difluorophenoxy)triisopropylsilane 
• 256417-11-5 2,3-difluoro-4-methoxy-benzaldehyde 
• 1010801-00-9 2,3-difluoro-4-((triisopropylsilyl)oxy)benzaldehyde 

Downstream Products

• 256417-11-5 2,3-difluoro-4-methoxy-benzaldehyde 
• 1010801-01-0 methyl 3-(2,3-difluoro-4-methoxyphenyl)-3-hydroxy-2,2-dimethylpropanoate 
• 1010801-02-1 methyl 3-(2,3-difluoro-4-methoxyphenyl)-2,2-dimethyl-3-oxopropanoate 
• 1010801-04-3 3-(2,3-difluoro-4-hydroxyphenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one 
• 1010802-00-2 C₂₉H₂₉F₅N₆O₄ 
• 1093857-65-8 2-[4-[2,3-Difluoro-4-(4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-3-yl)phenoxy]butyl]-5-(8-methoxy-2-trifluoromethylimidazo[1,2-a]pyridin-5-yl)-4,4-dimethyl-2,4-dihydro-pyrazol-3-one 
• 1093857-58-9 2-[4-[2,3-difluoro-4-(4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-3-yl)phenoxy]butyl]-5-(4-methoxy-2-trifluoromethylbenzo[d]thiazol-7-yl)-4,4-dimethyl-2,4-dihydro-pyrazol-3-one 
• 1010801-03-2 5-(2,3-Difluoro-4-methoxyphenyl)-4,4-dimethyl-2,4-dihydropyrazol-3-one 
• 1617504-91-2 (Z)-5-(10-hydroxy-11,12-difluorobenzylidene)imidazolidine-2,4-dione 

Relevant articles and documents

Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration

(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl) -5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti- inflammatory agent. N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition. Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition. Both dihydropyridazinone rings, in the core and extension, can be replaced by achiral 4,4-dimethylpyrazolone subunits and the core pyrazolopyridine by isosteric bicyclic heteroaromatics. In combination, these modifications afford potent dual PDE3/4 inhibitors that suppress histamine-induced bronchoconstriction in vivo and exhibit promising anti-inflammatory activity via intratracheal administration.

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.